Key result
Whey protein plus lycopene cuts CRP ~50% vs placebo and improves vascular function and lipids.
Why the study?
Does a combined formulation of whey protein and lycopene improve cardiovascular and inflammatory markers in patients with prehypertension?
RCT (n=40)
Does a combined formulation of whey protein and lycopene improve cardiovascular and inflammatory markers in patients with prehypertension?
A novel combined formulation of whey protein and lycopene improved surrogate markers of cardiovascular health, including lipids, inflammation, and vascular function, in patients with prehypertension.
Answers are grounded in this paper and cite their sources.
May support nutritional adjuncts for inflammation and vascular risk; leaves open confirmation in larger trials before practice change.
Parameters reflecting cardiovascular health and inflammation were studied in a pilot clinical trial conducted on 40 patients with prehypertension. The patients were treated with a new proprietary formulation of a whey protein (WP) isolate embedded into lycopene micelles (WPL) during a 1-month period. Control groups received lycopene or WP as a singular formulation or placebo pills for the same period of time. Combined WPL formulation of whey protein and lycopene has caused multiple favorable changes in the cardiovascular function (including a tendency to the reduced systemic blood pressure), the plasma lipid profile, and the inflammatory status of patients with prehypertension, whereas singular formulations of the compounds and placebo did not have such an effect. The reduction of plasma triglycerides and cholesterol fractions and almost two-fold decline in C-reactive protein (CRP) and inflammatory oxidative damage (IOD) levels as well as an increase in nitric oxide (NO), tissue oxygenation (StO(2)), and flow-mediated dilation values constitute the most significant benefit/outcome of the treatment with the combined formulation of whey protein and lycopene. The treatment did not affect the values of ankle-brachial index (ABI), body weight, and body mass index (BMI).
No takes yet. Share an insight, caveat, or question.
Petyaev et al. (2012) conducted an RCT in Prehypertension (n=40). Whey protein isolate embedded into lycopene micelles (WPL) vs. Lycopene, whey protein, or placebo was evaluated on Cardiovascular function, plasma lipid profile, and inflammatory status. A combined formulation of whey protein and lycopene led to an almost two-fold decline in C-reactive protein and improved vascular functions and plasma lipids compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: